Cardiogen

Cardiogen (Ala-Glu-Asp-Arg, AEDR) is a synthetic tetrapeptide (MW ~489.5 g/mol) from the Khavinson bioregulatory peptide family, proposed as a cardiac-specific peptide for myocardial regeneration and cardiovascular aging. It is claimed to modulate gene expression in cardiomyocytes, improving contractile function and reducing age-related cardiac fibrosis. Published primarily in Russian biogerontology literature.

1 independent Janoshik purity test cover Cardiogen across 1 vendor.

Category: Cardiovascular / Anti-Aging. Evidence rating: D (animal/preclinical only).

Clinical status: Russian clinical studies in elderly patients with cardiovascular disease. Not validated in Western trials.

Cardiogen is proposed to interact with DNA regulatory sequences in cardiomyocyte genes controlling contractile protein expression, mitochondrial function, and anti-fibrotic pathways. In aged cardiac tissue, it reportedly reduces collagen deposition, improves mitochondrial function, and enhances…

Safety considerations: Reported as well-tolerated in Russian clinical practice; No serious adverse events reported; Simple tetrapeptide with expected low toxicity.

Reviewed by the PeptideAtlas Editorial Team.

Cardiogen — measured properties

Amino-acid sequenceAla-Glu-Asp-Arg (AEDR)
Molecular weight~489.5 g/mol
Half-life~20-40 minutes
Production methodsynthetic
Anti-doping statusnot-listed
US regulatory statusResearch peptide. Not FDA-approved.

Cardiogen third-party purity tests

VendorBest tested purity
Peptide Gurus99.9%

Related peptides: Vesilute.

Frequently asked questions

Can Cardiogen help with heart disease?

Cardiogen has been studied only in Russian biogerontology clinics with limited published data. It should not replace established cardiovascular medications. If you have heart disease, work with a cardiologist using evidence-based treatments.

What is CARDIOGEN?

Cardiogen is a Khavinson bioregulator tripeptide (Ala-Glu-Asp) researched for cardiovascular tissue support and cardiac cell function in age-related decline.

What are the research benefits of CARDIOGEN?

CARDIOGEN has been studied for: Cardiac tissue support, Cardiovascular function, Myocardial health, Age-related heart support. Khavinson bioregulator; cardiovascular/cardiac tissue focus.

How does CARDIOGEN work?

Bioregulator peptide that may interact with gene promoter regions in cardiomyocytes, modulating expression of proteins involved in cardiac contractility and tissue maintenance.